Independent Expert Advises EMA on Benefit/Risk Communication
An independent report released by the European Medicines Agency on May 31, 2011, highlighted a number of recommendations to aid the agency in its communication of the benefits and risks of medicines. The report was the conclusion to a one-year project conducted by Frederic Bouder, PhD, at the behest of EMA, aiming to provide detailed, evidence-based input by analyzing the expectations and attitudes of the agency?s stakeholders toward communication on medicines.
An independent report released by the European Medicines Agency on May 31, 2011, highlighted a number of recommendations to aid the agency in its communication of the benefits and risks of medicines. The report was the conclusion to a one-year project conducted by Frederic Bouder, PhD, at the behest of EMA, aiming to provide detailed, evidence-based input by analyzing the expectations and attitudes of the agency’s stakeholders toward communication on medicines.
Tackling a number of questions, including how current communication channels build or undermine trust, how the risk communication process could be improved and how that process could bridge the gap between opposite views and expectations, the research studied a population that included regulators, industry and third parties (e.g., patient and consumer organizations, scientific opinion leaders, and medical and nonmedical journalists and editors).
Bouder created three case studies around Viracept, Acomplia, and Gardasil, and also conducted a cross-case analysis. The report concluded with four main recommendations:
- Establishing an external risk communication advisory board composed of experts the risk communication field. Parallels were drawn to a similar board already in place for the European Food Safety Agency.
- Forming a strategic view on what transparency means to enable a better response to stakeholders’ expectations and become more interactive in order to improve traditional information delivery.
- Being proactive in the involvement of patient organizations in sensitive issues, in particular where media coverage could escalate risk perception.
- Reviewing the format and timing of information delivery to target the audience and their needs more effectively. The report decried one-size-fits-all documents such as press releases for targeting neither experts nor the general public.
The agency has already started to implement some of the findings—evidence of its commitment to the five-year Road map to 2015 strategy.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
FDA Reopens Comment Period on HCP Immunogenicity Risk of Follow-on Recombinant Peptides
January 2nd 2025FDA is reopening the comment period for the Federal Register Notice, “Evaluating the Immunogenicity Risk of Host Cell Proteins in Follow-on Recombinant Peptide Products: Establishment of a Public Docket: Request for Information and Comments”, until March 3, 2025.
